Fig. 4: Time to next-line treatment and PFS after next-line treatment. | Blood Cancer Journal

Fig. 4: Time to next-line treatment and PFS after next-line treatment.

From: Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study

Fig. 4

a TTNT and b PFS after next-line treatment, defined as the time from randomization to the second disease progression or death from any cause, in patients receiving next-line treatment for relapse in the study. CLL chronic lymphocytic leukemia; PFS progression-free survival; TTNT time to next treatment.

Back to article page